Please use this identifier to cite or link to this item:
Title: TERT gene: its function and dysregulation in cancer.
Austin Authors: Colebatch, Andrew J;Dobrovic, Alexander ;Cooper, Wendy A
Affiliation: Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine and Molecular Cancer Prevention Program, La Trobe University, Melbourne, Victoria, Australia
Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia
Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia
School of Medicine, Western Sydney University, Sydney, New South Wales, Australia
Issue Date: Apr-2019
Date: 2019-01-29
Publication information: Journal of clinical pathology 2019; 72(4): 281-284
Abstract: In this review, we summarise the function and structure of telomerase reverse transcriptase (TERT) in humans, including its regulation. The dysregulation of telomerase through TERT promoter mutations across a range of cancers is discussed. The molecular mechanism activated by TERT promoter mutations is outlined. Finally, the timing of TERT promoter mutations during carcinogenesis is reviewed in the context of their potential utility as clinical biomarkers of malignant transformation.
DOI: 10.1136/jclinpath-2018-205653
ORCID: 0000-0001-5418-4229
Journal: Journal of clinical pathology
PubMed URL: 30696697
Type: Journal Article
Subjects: cancer
cancer genetics
cancer research
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.